Skip to content

FDA-approved botulinum toxins: U.S. approval timeline

FDA-approved botulinum toxin products in the United States include Botox / Botox Cosmetic, Myobloc, Dysport, Xeomin, Jeuveau, Daxxify, and Letybo. Counting Botox and Botox Cosmetic together gives seven product families. Six have aesthetic approvals; Myobloc has therapeutic indications only. The product labels linked below define each scope.

Botox is one brand of botulinum toxin, rather than the name of the entire category. For Botox and Botox Cosmetic specifically, see their FDA-approved uses and approval history.

Which Botulinum Toxin Brands Are FDA Approved?

Section titled “Which Botulinum Toxin Brands Are FDA Approved?”
U.S. brand / product familyToxin typeFDA-approved label scopePrescribing information
Botox / Botox CosmeticATherapeutic uses under Botox; aesthetic uses under Botox Cosmetic.Botox 🔗; Botox Cosmetic 🔗
MyoblocBTherapeutic: adult cervical dystonia and chronic sialorrhea.Myobloc label 🔗
DysportATherapeutic uses and aesthetic glabellar-line use.Dysport label 🔗
XeominATherapeutic uses and aesthetic upper facial lines.Xeomin label 🔗
JeuveauAAesthetic: adult glabellar lines.Jeuveau label 🔗
DaxxifyAAesthetic glabellar lines and therapeutic cervical dystonia in adults.Daxxify label 🔗
LetyboAAesthetic: adult glabellar lines.Current Letybo label 🔗

The six aesthetic products are Botox Cosmetic, Dysport, Xeomin, Jeuveau, Daxxify, and Letybo. This is a different count from the seven product families above: Myobloc is included in the therapeutic-and-aesthetic total, and Botox / Botox Cosmetic is grouped as one family. The count does not mean six products share every aesthetic indication. The U.S. FDA indication matrix details approved uses and patient limits by product.

Original approval dates establish when a product first entered the U.S. approval record. Later dates concern specific indication expansions, not a new original approval. For example, Xeomin’s original approval was therapeutic in 2010; its glabellar-line indication followed in 2011, and broader upper facial lines followed in 2024, as documented in the FDA records below.

Pending, refused, or otherwise unresolved U.S. applications are excluded from the approval sequence unless they enter the FDA approval record. Application acceptance and planned resubmissions are separate regulatory stages, tracked in U.S. botulinum toxin regulatory status.

The table is not a complete label-change database. It records original approvals and selected expansions that explain differences between product labels. Current prescribing information remains the authority for approved uses, preparation, warnings, dosing language, and patient populations.

DateBrand / active ingredientOriginal indication / contextFDA source
December 29, 1989Botox — OnabotulinumtoxinAFDA orphan-drug records list December 29, 1989 for strabismus and December 30, 1989 for blepharospasm; the current label preserves 1989 as the initial U.S. approval year.FDA orphan-drug record 🔗; current U.S. label 🔗
December 8, 2000Myobloc — RimabotulinumtoxinBTreatment of cervical dystonia to reduce severity of abnormal head position and neck pain associated with cervical dystonia.FDA approval letter 🔗
April 29, 2009Dysport — AbobotulinumtoxinACervical dystonia and glabellar-line approval anchors entered the U.S. record through the 2009 Dysport BLA package.FDA approval package 🔗; FDA approval letter 🔗
July 30, 2010Xeomin — IncobotulinumtoxinAAdult cervical dystonia and adult blepharospasm in previously treated patients.FDA approval letter 🔗
February 1, 2019Jeuveau — PrabotulinumtoxinA-xvfsTemporary improvement in the appearance of moderate to severe glabellar lines in adults.FDA approval letter 🔗; FDA label PDF 🔗
September 7, 2022Daxxify — DaxibotulinumtoxinA-lanmTemporary improvement in the appearance of moderate to severe glabellar lines in adults.FDA Drug Trials Snapshot 🔗; FDA approval package 🔗
February 29, 2024Letybo — LetibotulinumtoxinA-wlbgTemporary improvement in the appearance of moderate to severe glabellar lines in adults; BLA 761225, Hugel, Inc.FDA approval letter 🔗; FDA approval snapshot 🔗

Approval-era company names can differ from later ownership or commercialization roles. Botox has Allergan heritage within AbbVie / Allergan. Myobloc’s original approval was to Elan Pharmaceuticals and its 2019 supplement to Solstice Neurosciences; its later U.S. commercial context sits with Supernus. Dysport connects Ipsen with Galderma’s licensed aesthetic commercialization, while Xeomin connects to Merz. Jeuveau separates Daewoong’s manufacturing role from Evolus’s commercialization. Daxxify connects Revance development with Revance / Crown Laboratories, and Letybo connects to Hugel. Product and company entries provide those relationships beyond the dated FDA actions.

DateBrand / productApproved expansionFDA source
April 12, 2002Botox CosmeticTemporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults under the 2002 approval language.FDA approval letter 🔗
October 15, 2010BotoxProphylaxis of headaches in adults with chronic migraine.FDA approval package letter 🔗; FDA approval letter 🔗
July 2011XeominTemporary improvement in the appearance of moderate to severe glabellar lines in adults; the FDA label-change anchor identifies the change by month.FDA label-change anchor 🔗
September 11, 2013Botox CosmeticTemporary improvement in the appearance of moderate to severe lateral canthal lines, commonly discussed as crow’s feet.FDA approval letter 🔗; FDA 2013 label PDF 🔗
August 20, 2019MyoblocTreatment of chronic sialorrhea in adults.FDA supplement approval letter 🔗
August 11, 2023DaxxifyTreatment of cervical dystonia in adult patients.FDA approval letter 🔗; FDA orphan-drug approval record 🔗
July 5, 2024XeominTemporary improvement in the appearance of moderate to severe upper facial lines in adults: glabellar lines, horizontal forehead lines, and lateral canthal lines / crow’s feet, treated individually or simultaneously within the label.FDA approval letter 🔗; FDA 2024 label PDF 🔗
October 2024Botox CosmeticTemporary improvement in the appearance of moderate to severe platysma bands associated with platysma muscle activity in adults; the current FDA label identifies the indication and the October 2024 major-change month.FDA 2024 label PDF 🔗
June 25, 2026XeominTreatment of upper limb spasticity in patients 2 years of age and older now includes pediatric patients with spasticity associated with cerebral palsy; the earlier label excluded that population because of another product’s orphan-drug exclusivity.FDA supplement approval letter 🔗; FDA-approved June 2026 label 🔗; Merz announcement, June 26, 2026; one day after FDA approval 🔗

The Xeomin supplement approval letter was electronically signed on June 25, 2026; Merz announced the change on June 26. The approval date and company-announcement date are separate milestones.

Letybo’s February 29, 2024 approval followed earlier CRLs and resubmissions, as documented in its regulatory history. Those earlier actions are not approval dates. Its March 2025 U.S. commercial launch is a separate milestone in Hugel’s commercialization history.

On August 4, 2026, Allergan Aesthetics announced FDA acceptance for review of a BOTOX Cosmetic sBLA for masseter muscle prominence in adults. This is a proposed indication, so it is excluded from the approval table (Allergan Aesthetics sBLA announcement 🔗). The regulatory-status record separates this review from approved uses and from CRL responses.

The approval sequence shows how U.S. botulinum toxin history moved from therapeutic neurology and ophthalmology into aesthetic labeling, then into a broader set of branded type A products, multi-area facial labeling, neck aesthetic labeling, and expanded pediatric spasticity coverage. It also shows why one page cannot replace product-specific labels. A product can have a narrow aesthetic approval, a broader therapeutic label, a later indication expansion, or a company relationship that changed after approval.

For product comparison, start with the brand page, then check the current FDA prescribing information. For clinical-use interpretation, use indication pages as context, not as approval tables. For company interpretation, separate the approval holder, manufacturer, commercialization partner, and later owner where those facts differ.

For programs that have a public BLA, CRL, or resubmission history without U.S. approval, use U.S. botulinum toxin regulatory status rather than adding them to this approval sequence.

1. FDA approves a Xeomin label change removing the cerebral-palsy exclusion from pediatric upper limb spasticity. How should this change be interpreted?
2. Which source best establishes the historical date of an FDA indication approval?
3. FDA accepts a supplemental application for BOTOX Cosmetic masseter muscle prominence for review. What does this milestone establish?